Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer By Ogkologos - December 19, 2025 465 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an updated analysis of the EMBER-3 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Addressing Common Concerns Around Taking Opioids for Cancer-Related Pain: An Expert... July 5, 2023 Invasive Lobular Carcinoma Is Invisible On Mammograms, Isn’t A Lump April 4, 2019 Airline Won’t Let Dad And Newborn On Plane, So Kind Stranger... February 19, 2020 El cáncer en mi comunidad: Cómo acceden las personas con cáncer... August 12, 2021 Load more HOT NEWS Caregivers Empower the Next Generation of Cancer Care Clinical and Biological Activity of Patritumab Deruxtecan in Patients with HR-positive,... EMA Recommends Extension of Therapeutic Indications for Retifanlimab Drug Combo JAKs Up Immunotherapy in Two Clinical Trials
